Global search

Find data and evidence

Type at least 2 characters. Use arrow keys to review and Enter to open.

Disease overview

Parasitic
Evidence-backed information EN 5/7 applicable sections · ZH 5/7 applicable sections Updated Oct 23, 2026

Leishmaniasis is a group of parasitic diseases caused by more than 20 Leishmania species and transmitted by female phlebotomine sandflies [1][2]. The three main clinical forms are cutaneous, visceral (kala-azar), and mucocutaneous, with cutaneous being the most common and visceral the most severe [1][2]. Globally, over 1 billion people live in endemic areas and are at risk, while cutaneous leishmaniasis alone affects around 12 million people with 2 million new cases yearly [3][2]. The World Health Organization classifies it as a neglected tropical disease that remains emerging and insufficiently controlled [3][4].

Read the full clinical and epidemiological profile 6
Definition

Leishmaniasis refers to illness arising from infection by any species of the protozoan parasite Leishmania, not merely parasitic presence, since most infected persons never develop symptoms [1][2]. It is a vector-borne disease transmitted through the bite of infected female sandflies and encompasses cutaneous, visceral, and mucocutaneous presentations [1][2]. Cutaneous leishmaniasis is typically a zoonotic infection maintained in wild or semi-domesticated animal reservoirs such as rodents and dogs [5].

Clinical features

Cutaneous leishmaniasis produces skin lesions such as nodules, painless ulcers, crusted plaques, or ulcers on exposed body parts, sometimes numbering up to 200 and healing with permanent scars [1][2][5]. Visceral leishmaniasis (kala-azar) is life-threatening and marked by irregular fever, weight loss, anaemia, and enlargement of spleen and liver, with near-universal fatality if untreated [1][2]. Mucocutaneous leishmaniasis destroys mucous membranes of the nose, mouth, and throat, causing disability and social exclusion [1][2]. People living with HIV who acquire Leishmania infection face high likelihood of full disease, relapse, and death [4].

Epidemiology

Leishmaniasis is endemic across almost 100 countries, with over 1 billion people at risk and cutaneous disease accounting for roughly 12 million existing and 2 million annual cases [3][2]. The Americas report about 80% of global cutaneous cases, and Brazil is the principal endemic country for visceral leishmaniasis in that region [4][2]. Visceral leishmaniasis is highly endemic in Iraq, Somalia, Sudan, and Yemen, while East Africa experiences frequent outbreaks of the visceral form and all types are endemic [4]. Cutaneous leishmaniasis is highly endemic in Algeria, whereas West Africa lacks sufficient epidemiological data, and imported cases mainly originate from Africa and the Americas [4]. Environmental and climatic changes, urbanization, deforestation, and migration further shape disease incidence and spread [4].

Transmission

The parasites are transmitted to humans by the bite of infected female phlebotomine sandflies, tiny 2–3 mm insects that feed on blood to mature eggs [1][2]. More than 90 sandfly species are known vectors, and over 70 animal species including humans can serve as parasite reservoirs [4]. In most cases, cutaneous leishmaniasis is zoonotic, with transmission via Phlebotomus sandflies from rodent or dog reservoirs [5].

Prevention

Control of leishmaniasis requires strengthened vector control, improved diagnostics, and development of safe and effective vaccines, which are currently lacking [3]. Because the disease primarily affects poor populations, commercial investment in diagnostics, drugs, and vaccines remains inadequate [3].

References
  1. 1 World Health Organization. Leishmaniasis [Internet]. cited 23 Oct 2026. Available from: https://www.who.int/news-room/questions-and-answers/item/leishmaniasis
  2. 2 World Health Organization. Leishmaniasis [Internet]. cited 23 Oct 2026. Available from: https://www.who.int/health-topics/leishmaniasis
  3. 3 de Vries HJC et al. Cutaneous Leishmaniasis: A 2022 Updated Narrative Review into Diagnosis and Management Developments. Am J Clin Dermatol. 2022 Nov. PMID: 36103050. doi: 10.1007/s40257-022-00726-8. PubMed: https://pubmed.ncbi.nlm.nih.gov/36103050/
  4. 4 World Health Organization. Leishmaniasis [Internet]. cited 23 Oct 2026. Available from: https://www.who.int/news-room/fact-sheets/detail/leishmaniasis
  5. 5 Mokni M et al. [Cutaneous leishmaniasis]. Ann Dermatol Venereol. 2019 Mar. PMID: 30879803. doi: 10.1016/j.annder.2019.02.002. PubMed: https://pubmed.ncbi.nlm.nih.gov/30879803/
Coding Register
ICD-10
B55
ICD-11
1F51
Data coverage

Loading current data…

Country surveillance trends

Choose a country, source, and measure. Each line retains its published reporting period and definition.

Loading data…

Coverage

Reporting countries and regions

The map shows reporting coverage. Select a measure or open a shaded location to inspect its data.

Loading current data…

Surveillance pattern

Year × month seasonality by country

Review one country’s published monthly values by year. Empty cells indicate values the source did not publish.

Research Radar

Recent related research

View all research →

Showing 5 of 114 related publications.

Literature links are provided for discovery and do not alter or validate the surveillance series above.

Loading official alerts…

Downloads and methods

Choose a time range and download CSV, JSON or XLSX files.

Partitioned public data

Choose a time range and format

Download archives have their own release date and may differ from the live curves.